Public hesitancy for AI-based detection of neurodegenerative diseases in France
Abstract Recent advances in artificial intelligence (AI) have made it possible to detect neurodegenerative diseases (NDDs) earlier, potentially improving patient outcomes. However, AI-based detection tools remain underutilized. We studied individual valuation for early diagnosis tests for NDDs. We c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-11917-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Recent advances in artificial intelligence (AI) have made it possible to detect neurodegenerative diseases (NDDs) earlier, potentially improving patient outcomes. However, AI-based detection tools remain underutilized. We studied individual valuation for early diagnosis tests for NDDs. We conducted a discrete choice experiment with a representative sample of the French adult population (N = 1017). Participants were asked to choose between early diagnosis tests that differed in terms of: (1) type of test (saliva vs. AI-based tests analysing electronic health records); (2) identity of the person communicating the test results; (3) sensitivity; (4) specificity; and (5) price. We calculated the weights in the decision for each attribute and examined how socio-demographic characteristics influenced them. Respondents revealed a reduced utility value when AI-based testing was involved (valuated at an average of €36.08, CI [€22.13; €50.89]) and when results were communicated by a private company (€95.15, CI [€82.01; €109.82]). We interpret these figures as the shadow price that the public attaches to medical data privacy. Beyond monetization, our representative sample of the French population appears reluctant to adopt AI-powered screening, particularly when performed on large sets of personal data. However, they would be more supportive when medical expertise is associated with the tests. |
|---|---|
| ISSN: | 2045-2322 |